General cardiologists and interventional cardiologists only: Following Danger-Shock, would you enroll in a second trial of STEMI with cardiogenic shock in patients without anoxic encephalopathy, randomizing to Impella versus control (pressors +|- balloon pump +|- ECMO)?

Final poll results: with 277 responses, after ULTIMATE -DAPT, 67% are ready for shorter DAPT regimens after PCI in ACS, with most of those ready for 1 month only. 33% still say 1-year DAPT! Not sure why. No one bleeds until they bleed.

Final poll results: with 677 responses, after PREVENT, 35% are ready to treat non-flow-limiting asymptomatic vulnerable plaques with preventive PCI to improve prognosis. 65% are not yet believers. 4 other trials are ongoing and more are being designed.

Final poll results - with 440 responses 44% are “sold” after Danger-Shock that Impella use should be routine in appropriate pts with AMI-CS. But 56% of cardiologists are not there yet. Is a 2nd trial possible?

This is always a great course with complex cases and excellent talks.

After all the recent IVUS and OCT guidance trials of PCI, how will your use of intravascular imaging guidance change? Percent of all PCIs (choose best answer):

After ULTIMATE-DAPT, what anti-platelet regimen will you use beginning at 1 month in most pts who remain stable on DAPT after PCI in ACS for 1 month? A=aspirin, P=P2Y12 inhibitor

After the SMART trial, what type of TAVR valve will you most likely use in small aortic annuli?

After the PREVENT trial, regarding PCI of vulnerable plaque, will you:

After DANGER SHOCK, in most pts with STEMI and cardiogenic shock w/o likely anoxic brain injury, will you use:

Our publication today in JACC describing the outcomes of MitraClip in atrial compared with ventricular FMR from 5 studies (4 with outcomes data). MR reduction to <=2+ was comparable in aFMR and vFMR (RR: 0.99; 95% CI: 0.96-1.02; P=0.53) as was 1-yr death or HFH (fig).

Following the excellent LIFE-BTK results, it’s time to bring the new and improved BVS (ESPRIT) back to the cors! Very late outcomes will be improved by leaving nothing behind.

Just publ in JSCAI our first-in-human study with a new integrated AI-enabled OCT-NIRS imaging catheter that has enhanced resolution and IVUS-like depth penetration (even better in calcium). Angio co-reg w/ automated EEM, lipid and Ca detection. Free link:
authors.elsevier.com/sd/article/S27…

2/4 OCT/IVUS vs angio PCI guidance also reduced cardiac death by 45%, def/prob ST by 48%, def ST by 61%, TLR by 28% and TLF by 29% at a weighted mean FU of 24.7 months. All results were similar with OCT and IVUS. Free to download: authors.elsevier.com/a/1ie90V-4XL6EY

For those feeling content with their life’s work….

Our perspective in EHJ published on the progress made, but the questions that remain with transcatheter treatment of tricuspid regurgitation. “From TriValve to TRILUMINATE to TRISCEND: what have we learned?” urldefense.proofpoint.com/v2/url?u=http-…